Choose the experimental features you want to try

This document is an excerpt from the EUR-Lex website

Document 62015CN0662

    Case C-662/15: Request for a preliminary ruling from the Oberlandesgericht Düsseldorf (Germany) lodged on 14 December 2015 — Lohmann & Rauscher International GmbH & Co. KG v BIOS Naturprodukte GmbH

    IO C 118, 4.4.2016, p. 4–5 (BG, ES, CS, DA, DE, ET, EL, EN, FR, HR, IT, LV, LT, HU, MT, NL, PL, PT, RO, SK, SL, FI, SV)

    4.4.2016   

    EN

    Official Journal of the European Union

    C 118/4


    Request for a preliminary ruling from the Oberlandesgericht Düsseldorf (Germany) lodged on 14 December 2015 — Lohmann & Rauscher International GmbH & Co. KG v BIOS Naturprodukte GmbH

    (Case C-662/15)

    (2016/C 118/05)

    Language of the case: German

    Referring court

    Oberlandesgericht Düsseldorf

    Parties to the main proceedings

    Applicant and appellant: Lohmann & Rauscher International GmbH & Co. KG

    Defendant and respondent: BIOS Naturprodukte GmbH

    Question referred

    Are Article 1(2)(f), Article 11, point 13 of Annex I and the last indent of point 3 of Annex VII [to Council Directive 93/42/EEC of 14 June 1993 concerning medical devices] (1) to be interpreted as meaning that a further conformity assessment procedure is required for the marketing of a Class I medical device, which has been made subject to a conformity assessment procedure by the manufacturer and lawfully bears the CE marking affixed by the manufacturer, where the information relating to the central pharmaceutical number (Pharmazentralnummer) on the outer packaging of the medical device has been concealed by a sticker which provides the importer’s details and the central pharmaceutical number granted to that importer, the other information remaining visible?


    (1)  OJ 1993 L 169, p. 1.


    Top